| In Vivo |
Contulakin G exhibits potent analgesic activity in three pain models in rats following intrathecal delivery, namely in tail-flick (acute pain), formalin test, and CFA-induced allodynia inflammatory pain[1]. Contulakin G (0-3 nmoL, Intrathecally) significantly decreases flinching behavior in rats[2]. Contulakin G (50-500 nmoL, Intrathecally) produces a dose-dependent increase in the thermally evoked skin twitch latency by 30 min after administration in dogs[2]. Animal Model: Male Holtzman rats (300-375 g)[2] Dosage: 0.03, 0.1, 0.3, and 3 nmol Administration: Intrathecally, administered as a 10-μL bolus followed by a 10-μL saline flush Result: Produced a significant decrease in flinching in all phases of the formalin test in rats. Animal Model: Purpose-bred beagle dogs (9-12 kg)[2] Dosage: 50, 150, or 500 nmol Administration: Intrathecally Result: Produced a dose-dependent increase in the thermally evoked skin twitch latency at 30 min after dosing in dogs, which reached statistical difference as compared to vehicle at 500 nmol.
|
